Rival BTK degraders face off, as do bispecific Cars and T-cell engagers.
ApexOnco Front Page
Recent articles
Data will be presented on Kura’s Komzifti and Syndax’s Revuforj in first-line AML.
The latest projects newly into human trials include BNT3212.
But results come from a curated dataset, with no in-trial comparator.
Global data are in the same ballpark as Chinese results presented earlier this year.
A common mutation comes into play for PRMT5 inhibition.
Investors now have more reasons to doubt Harmoni's ability to back US approval.
Early data with IDE849 look better those with Zai’s zocilurtatug pelitecan.
